The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for survival in patients with resectable esophageal squamous cell carcinoma (JCOG2305A).
 
Motoo Nomura
Honoraria - Bristol-MyersSquibbK.K.; MSD; ONOPHARMACEUTICALCO.,LTD.
Consulting or Advisory Role - ONOPHARMACEUTICALCO.,LTD.
 
Tomohiro Kadota
No Relationships to Disclose
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Ryunosuke Machida
No Relationships to Disclose
 
Ryosuke Kita
No Relationships to Disclose
 
Yoshinori Ito
No Relationships to Disclose
 
Yuko Kitagawa
Honoraria - Asahi Kasei; ASKA Pharmaceutical Co., Ltd.; Astellas Pharma; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Foundation for Innovative Drug Discovery Science; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED; EA Pharma; Eisai; Ethicon; Intuitive Surgical; Japan Lifeline Co.,Ltd.; Kaken Pharmaceutical; Kowa; Miyarisan pharmaceutical; MSD K.K.; Nippon Covidien; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Smart Hospital Inc.; Sysmex; T-PEC CORPORATION; Taiho Pharmaceutical; Takeda; Toray Industries; TSUMURA & CO.
Consulting or Advisory Role - Bristol-Myers Squibb K.K.; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Nippon Covidien (Inst); Otsuka (Inst); Otsuka (Inst); Sumitomo Pharma Co., Ltd. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); TSUMURA & CO. (Inst)
 
Hiroyuki Daiko
No Relationships to Disclose
 
Yasuhiro Tsubosa
No Relationships to Disclose
 
Yoshiaki Nagatani
No Relationships to Disclose
 
Hiroki Hara
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; Miyarisan pharmaceutical; MSD; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan
Research Funding - Abbvie (Inst); ALX Oncology (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Henlius (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Keiko Minashi
Research Funding - Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); PPD-SNBL (Inst); Taiho Pharmaceutical (Inst)
 
Takeshi Kajiwara
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Taiho Pharmaceutical
 
Kazuo Koyanagi
No Relationships to Disclose
 
Takashi Ogata
Speakers' Bureau - Bristol Myers Squibb Foundation; MSD; Ono Pharmaceutical
 
Takako Yoshii
Honoraria - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
 
Takeo Fujita
No Relationships to Disclose
 
Satoru Matsuda
Honoraria - Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo/Lilly; Ethicon; MSD; Olympus Medical Systems; Ono Pharmaceutical
 
Takahiro Tsushima
Honoraria - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hiroya Takeuchi
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo/Astra Zeneca; EA Pharma; Intuitive Surgical; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Medicon; Medtronic; Miyarisan pharmaceutical; MSD K.K; Nihonkayaku; Novartis; Olympus Medical Systems; Ono Pharmaceutical; Otsuka; Sysmex; Taiho Pharmaceutical; Tsumura & Co.
Research Funding - Chugai Pharma (Inst); Kaken Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Tanabe Mitsubishi Pharmaceutical (Inst)